The deal focuses on a biosimilar candidate currently in development for the treatment of multiple oncology indications. Biosimilars are gaining recognition for their potential to offer cost-effective alternatives
The funds will be channelled towards advancing multiple proprietary pipeline programmes into clinical trials, including a highly specific AKT1 E17K inhibitor and a KRAS selective inhibitor. This significant
This development creates new pathways for the vaccine’s procurement, distribution, and reimbursement by both public and private payers. In response to the global mpox outbreak, since 2022, JYNNEOS
Duchenne is a genetic disorder, primarily affecting boys and is known to be fatal. This disease is claimed to affect roughly one in every 3,500 to 5,000 live
Utidelone’s unique properties allow it to cross the blood-brain barrier (BBB), a capability supported by both preclinical and clinical studies. A Phase II study involving utidelone in combination
This sNDA extends the indication of Vemlidy, a once a day 25mg tablet for usage in children aged six years and above weighing a minimum of 25kg with
Sperogenix Therapeutics, the company’s rare disease partner in China, filed the application with the NMPA. The Center for Drug Evaluation (CDE) of the NMPA accepted the filing after
This collaboration is expected to leverage Cipla’s extensive distribution network to enhance the reach of Sanofi India’s CNS products. Under the agreement, Cipla will handle the distribution and
With the deal closing, the merged business will now function under the name Q32 Bio. Concurrent with the merger’s closure, Q32 Bio also finalised a $42m private placement.
This endorsement is a significant step towards the availability of Fabhalta for PNH patients in Europe. The positive opinion is based on data from two Phase III clinical
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.